<- Go Home
Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Market Cap
$6.5M
Volume
1.7M
Cash and Equivalents
$3.3M
EBITDA
-$7.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$4.17
52 Week Low
$0.77
Dividend
N/A
Price / Book Value
1.01
Price / Earnings
-0.22
Price / Tangible Book Value
1.01
Enterprise Value
$3.2M
Enterprise Value / EBITDA
-0.40
Operating Income
-$7.3M
Return on Equity
320.96%
Return on Assets
-104.18
Cash and Short Term Investments
$3.3M
Debt
N/A
Equity
$4.3M
Revenue
N/A
Unlevered FCF
-$3.0M
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium